Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease

• Status: Completed
• Trial end date: 2005-08-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with either lanthanum carbonate or sevelamer hydrochloride

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shire
• Treatments: Sevelamer

Criteria

Inclusion Criteria:

• Patients receiving haemodialysis for ESRD

• Patients must have received haemodialysis for chronic renal failure three times per week for at least the previous 2 months

Exclusion Criteria:

• Pregnant or lactating women

• Patients with clinically significant uncontrolled concurrent illness, a life-threatening malignancy or current multiple myeloma

• Patients who are HIV+

• Patients with any significant bowel obstruction, active inflammatory bowel disease, GI motility disorders, or a history of major GI surgery within the last 6 months